Skip to main content
OpenTrials
Completed

NCT Number: NCT03243435

Sienna+MR Long-term Uptake

In a previous study in 2012/2013 patients were injected a superparamagnetic iron oxide for sentinel lymph node detection. In this follow up study we want to investigate how much of this tracer is still detectable.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Observational

Primary location

Kantonsspital Baden

Baden, Canton of Aargau, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

inclusion:

  • participation in previous study
  • informed consent
  • no contraindications for MRI scan

exclusion:

  • contraindications for MRI scan

Treatment and study plan

Native 1,5 Tesla breast MRI

Procedure

Primary outcomes

  1. I) Analysis if the supraparamegnetic Tracer is still detectable

    Time frame: 04/2017

    Analysis by two expert radiologists

Secondary outcomes

  1. Analysis to which degree of impairment of Imaging is detected

    Time frame: 04/2017

    Description as "no impairment", impairment, but Interpretation of Images possible", "impairment, Image Interpretation impossible"

Sponsors and collaborators

Lead sponsor

Kantonsspital Baden

Other

Registry information

Official study title

Feasibility of Breast MRI After Sentinel Procedure for Breast Cancer With Superparamagnetic Tracers

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Aug 9, 2017
Registry last updated
Aug 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.